Jaffer Ajani, MD
Enriched profileProfessor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine · The University of Texas MD Anderson Cancer Center
Jaffer Ajani is Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 1,745 publications with 118,781 citations (h-index 154); ClinicalTrials.gov lists 21 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists Jaffer Ajani as a Highly Cited Researcher (Cross-Field, 2021-2025).
Data verified 25 Aug 2026
Overview
Updated 14 Oct 2026
Jaffer Ajani, M.D., is Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. The public record shows 1,745 publications with 118,781 citations (h-index 154), centered on Gastric Cancer Management and Outcomes, Esophageal Cancer Research and Treatment, Colorectal Cancer Treatments and Studies. It also documents an investigator role on 21 registered clinical trials, industry payments reported by 27 companies, 5 NIH-funded awards (2008–2024).
- Most recent indexed publication: 2026 · Annals of surgical oncology
- Top research focus: Gastric Cancer Management and Outcomes
- 21 registered trials on ClinicalTrials.gov
- Open Payments reporting from 27 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 58 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 730.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 21 registered studies on ClinicalTrials.gov. The most recent:
- Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer
Sponsor: M.D. Anderson Cancer Center
- Trial of DFP-14927 in Advanced Solid Tumors
Sponsor: Delta-Fly Pharma, Inc.
- Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma
Sponsor: M.D. Anderson Cancer Center
Industry payments
Updated 14 Oct 2026
27 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- BeOne Medicines USA, Inc.Program year202512 payments$11,612openpaymentsdata.cms.gov ↗
- Gilead Sciences, Inc.Program year20252 payments$10,935openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year20256 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
58.4%Serotonin-3 Receptor Antagonist48.7%Ondansetron Odt60%Ondansetron Hcl40%Part D≥27 patientsProton pump inhibitor9.7%Pantoprazole Sodium100%Part D<11 patientsNervous system
28.3%Phenothiazine28.3%Prochlorperazine Maleate100%Part D≥29 patientsRespiratory
13.3%Opioid Agonist13.3%Hydrocodone-Acetaminophen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
5 NIH research awards on record, funded 2008–2024 per NIH RePORTER. The latest:
- Common Stem Cell of Origin for Junctional and Gastric Adenocarcinoma
Wake Forest University Health Sciences
FY2026$935,434R01CA272906 - Common Stem Cell of Origin for Junctional and Gastric Adenocarcinoma
Wake Forest University Health Sciences
FY2025$949,184R01CA272906 - Common Stem Cell of Origin for Junctional and Gastric Adenocarcinoma
University of Houston
FY2024$888,662R01CA272906
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.
The New England journal of medicine
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jaffer-ajani-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Jaffer-A-Ajani-38511121
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - ResearchGate
researchgate.net/scientific-contributions/Jaffer-A-Ajani-MD-80392321
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - ResearchGate
researchgate.net/scientific-contributions/Jaffer-Ajani-2249649039
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - Google Scholar
scholar.google.com/citations
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →scholar.google.com ↗
Mentions by others
where others cite or feature them- Instagram
instagram.com/p/DCZmh0-R-U3
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Apple Podcasts
podcasts.apple.com/us/podcast/onclive-on-air/id1410308406
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →fda.gov ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →nccn.digitellinc.com ↗
- Associate Editor
Gastric Cancer journal
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗ - Editorial Board
Journal of the National Comprehensive Cancer Network
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Cross-Field20212022202320242025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →giantsofcancercare.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Media & interviews
press, podcasts and appearances- Featured expert commentary
"Metastatic Gastroesophageal Cancers: Expert Perspective", The ASCO Post
2016verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Video perspective series on gastric cancer treatment
challenges, and care disparities, Healio "Gastric Cancer Video Perspectives"
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com ↗ - Podcast guest
"Gastroesophageal Cancers with Dr Jaffer Ajani", Oncology Today with Dr Neil Love (Research To Practice)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncologytoday.researchtopractice.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancernetwork.com ↗
- Interview series
"Additional Advances in Esophagogastric Cancer Research and Clinical Trials with Jaffer Ajani, MD", Oncology Data Advisor
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncdata.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Charles Fuchs, MD, MPH
Tubulis GmbH
John Buse, MD
University of North Carolina School of Medicine